Home > About Bizmedic > Subsidery
 
   

BizBiotech Overview
Our Mission
 To increase the length and quality of human life by developing novel anti-cancer drugs with high
  efficacy and low toxicity
 To develop a new model for drug development leveraging proven best practices from other
  industries
 Conventional Cancer Drugs
  Cancer drugs now on the market offer inconsistent results
  - 15% efficacy is considered acceptable
- Most are toxic to healthy cells and organs
- During treatment, patients risk greater harm from cancer drugs than from the cancer itself
   
 Nonetheless, global sales of cancer drugs consistently grow by 10% every year and will reach
$26 billion in 2003
Novel cancer drug discovery: YC-1
 YC-1-based therapy literally suffocates cancer by blocking the master protein that supplies
  necessary oxygen to growing malignant cells.
 Tests on a variety of human cancers in immunodeficient mice prove the efficacy of
   YC-1-based therapy
  

- Dramatically shrinks established tumors
- Hinders development of emerging tumors
- Virtually no impact on adjacent healthy tissues

YC-1 and the global oncology market
 YC - 1 based cancer therapy will likely make a significant impact on the global oncology market
 YC - 1 based cancer therapy is Bizbiotech's protected science and intellectual property
  - Five patents in progress
- Substantial research published and reviewed since 1999
 Aggressive research strategy will drive YC-1 through IND and FDA approval process
  - Preclinical studies to be completed within two years
- Approval for market as early as five years

BizBiotech Company
BizBiotech Background
 

International team of science and business experts with intellectual property in a promising novel
  cancer therapy
 

Cancer drug development for YC-1 began in 1999
 

 Team deferred corporate formation until findings confirmed oncological effectiveness beyond any
  doubt.
 BizBiotech's approach is a synergy between business and science.
  Business strategy is guided by the spirit of scientific method
Scientific process is inspired by proven best business practices for maximizing returns at each stage of the development pipeline
   - Business strategy is guided by the spirit of scientific method
   - Scientific process is inspired by proven best business practices for maximizing returns at each stage of the development pipeline
  
Respected journals affirm the potential of YC-1?based cancer therapies
 

“ There seems little question that
hypoxia inducible pathways and HIF-1
are therapeutic targets worthy of
attention. Important oncogenic signaling
pathways regulate HIF-1 independently
of hypoxia, adding to the potential
importance of this factor … .

”Journal of the National Cancer Institute"
(Vol. 95, No. 7, April 2, 2003)

   
 

So, it seems from this initial study
that YC-1 could be used to ‘suffocate'
many types of tumour by preventing
their ability to cope with hypoxia. Its
low toxicity in the mouse study is an
important advantage …”

Nature Reviews: Cancer (Vol. 3 , May 2003)

   
 

HIF-1/ HIF-2 pharmacological inhibitors

Inhibitor

Target

References

YC-1 stimulator(sGC)

Soluble guanylyl cycle

106

2-ME2

Microtubule destabilizer

103

Taxol

Microtubule Stabilizer

103

Vincristine

Microtubule Stabilizer

103

1-methylpropy-2-imidazolyl disulphide

Thioredoxin reductase

75

Pleurotin

Thioredoxin reductase

75

Rapamycin/ CC1779

TOR

90, 95, 96

LY294002, wortmannin

Pl3K

71, 82, 83, 84, 86, 96

Geldanamycin

HSP90

70, 73

Quinocarmycin

HRE transcriptional activity

99

PD98059

MEKK

91,92

2-ME, 2-methyoxyoestradiol : HIF, hypoxia-inducible factor : HRE,
hypoxia-response element : HSP90, heat-shock protein90; MEKK, Mitogen-activated protein kinase kinase kinase; Pi3K, phosphatidylinositol 3-kinase;TOR,
target of raparmycin

   
YC-1's efficacy as an anti-cancer agent is documented in published articles
 
1999.1
Testing With human liver tumor
- initial in vitro and in vivo tests confirm efficacy of YC-1 on liver cancer(hep3B)

2002.1
Additional testing With human tumor types
- Additional nude mouse tests confirm efficacy of YC-1 on other human tumors (kidney, uterine cervix , nervous system, stomach, and prostate)
2002.8
Mannose analog synthesis and testing
- YC-1 mannose analog designed to improve water solubility - more nude mouse tests confirm efficacy of analog on liver cancer.

2003. 3
Comparison with conventional drugs

- Additional nude mouse tests demonstrate greater efficacy and lower toxicity of YC-1 compared to adriamycin and cisplatin.


Article 1

“ Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells ”
- Biochemical Pharmacology (2001) -


Article 2

“Oxygen-dependent and -independent regulation of HIF-1 alpha ”
- Journal of Korean Medical Science (2002) -


Article 3

“ YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1 ”
- Journal of the National Cancer Institute (2003) -

Potential benefits of partnerships
 Reduced development cost
   - An alliance partner with R&D infrastructure could lower development costs.
- Partner may already have incurred cost of synthesizing and testing analogs.
 Reduced time to market
   - partner may already have analogs ready for IND.
- A partner may possess expertise to speed up regulatory process.
  Increased probability of financial success
   - Leverage partner's experience in drug development.
- Combine IP assets to form more solid IP position.
 Increased revenue penetration
   - A licensing partner may possess global marketing network.
- A licensing partner may leverage their brand to increase penetration.